Related Experiment Video
Updated: May 23, 2026
09:03
Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies
Published on: June 30, 2023
Platelet-associated angiogenesis regulating factors: a pharmacological perspective
Aneta Radziwon-Balicka1, Cesar Moncada de la Rosa, Paul Jurasz
1Faculty of Pharmacy and Pharmaceutical Sciences, 3-142E Katz Group-Rexall Centre for Pharmacy & Health Research, University of Alberta, Edmonton, AB T6G 2E1, Canada.
Canadian Journal of Physiology and Pharmacology
|April 20, 2012
Summary
Platelets release factors that promote new blood vessel growth (angiogenesis). This review covers platelet angiogenesis regulators, their functions, and pharmacological control, including the inhibitor angiostatin.
Area of Science:
- Hematology
- Vascular Biology
- Oncology
Background:
- Platelets are crucial for hemostasis and also regulate angiogenesis.
- Over 20 angiogenesis regulators (promoters and inhibitors) are found in platelets.
- These factors influence wound healing, tumor growth, and ischemia.
Purpose of the Study:
- To review platelet-associated angiogenesis regulators.
- To discuss their impact on blood vessel formation.
- To explore pharmacological control mechanisms.
Main Methods:
- Literature review of platelet function and angiogenesis.
- Analysis of identified angiogenesis regulators in platelets.
- Examination of pharmacological inhibition of platelet-derived factors.
Main Results:
- Platelets release numerous angiogenesis promoters and inhibitors.
- Platelet-derived angiostatin acts as an endogenous inhibitor.
- Anti-platelet agents can suppress platelet-stimulated angiogenesis.
Conclusions:
- Platelets play a dual role in angiogenesis.
- Understanding platelet regulators is key for therapeutic strategies.
- Pharmacological targeting of platelet factors offers therapeutic potential.
Related Concept Videos
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
01:10Mechanism of Angiogenesis
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:22Formation of the Platelet Plug
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...